Vaccine Adjuvants Market Share, Size, Trends, Industry Analysis Report, By Product Type (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), and Other Types); By Route of Administration (Oral, Subcutaneous, Intranasal, Intramuscular, Intradermal, and Others); By Disease Types; By Application (Research Application and Commercial Application), By Regions; Segment Forecast, 2020 –2027

Report Summary

2019年全球疫苗辅助辅助人的辅助辅助人数占585.3百万美元，预计将在2020-2027期间的CAGR增长10.68％。促进全球疫苗辅助市场的增长的因素包括过去十年传染病的快速激增，如SARS，埃博拉病毒，中东呼吸道综合征（MERS），最近由政府持续持续的Covid-19大流行，未核心佐剂的某些疾病，研究和创新的需求，以及生物制药公司的参与增加。

佐剂是在发育疫苗的成分，以通过在该人身上产生强烈的免疫应答来提高其效率。这些是由具有天然存在的佐剂的弱化细菌组成，以产生强免疫原性。目前正在使用的一些不同的佐剂包括铝盐（无定形铝羟基磷酸硫酸铝（AAH），硫酸氢钾和氢氧化铝，磷酸铝），AS04（单磷脂脂质A（MPL）和铝盐的混合物），MF59（水乳液中的Squalene基油），AS01（MPL和QS-21的混合物）和CPG 1018（胞嘧啶磷酸鸟嘌呤）。

Know more about this report:request for sample pages

Market Dynamics

Growth Drivers

全球市场主要是由孔蒂nuous spike in infectious diseases outbreaks in the last decade, killing a large section of the world population. Few notable examples in the include:

• The severely acquired respiratory syndrome (SARS) which originated from Hong Kong in 2002, had claimed more than 922 lives, with around 8,422 confirmed cases globally, within its one year of the life cycle. It had a mortality rate of 10.9% according to the estimates of WHO.
• 2009年H1N1病毒大流行引起的猪流感率为约284,500人。只是其他类型的流感，它也显示出复发发烧，喉咙痛，红色的眼睛，咳嗽和鼻塞的症状。
• The Ebola outbreak occurred between 2013 to 2016 in West African countries including Guinea, Liberia, and Sierra Leone claimed around 11,300 lives. This outbreak was the deadliest outbreak Ebola outbreak booth in infection rate and mortality rate.
• In 2015, North and South America witnessed an outbreak of Zika virus and reported more than 5,168 cases. The transmission was primarily spread North America with travelers returning the outbreak zones at their home places.

最近正在流行虽然不是lethal as its predecessors but rate of infection is alarming. According to the statistics published by Johns Hopkins University, by 24 June 2020, the virus has infected more than 9 lacs people and took lives of around 4.8 lacs, across the globe. Moreover, according to the International Monetary Fund (IMF), it is expected that the global economy would lose more than USD12 trillion from 2020 to 2021.

Challenges

全球市场与诸如与疫苗相关的副作用等诸如副作用，以及其开发中的低研究活动。佐剂相关的系统性毒性导致恶心，发热，关节痛，少数病例，腹泻，头痛，肌痛和嗜睡。理论风险包括组织超敏反应（自身免疫紊乱），与人抗原的交叉反应，如肾小球基底膜，导致肾小球肾炎，致癌物和低血基血症。此外，由于在注射部位在氢氧化铝衍生的丙氨酸疫苗，巨噬菌肌肌肌肉叶炎（肌肉炎症障碍）。

Vaccine Adjuvants Market Report Scope

The market is primarily segmented on the basis of Product Type, By Route of Administration, By Disease Type, By Application, and geographic region.

通过产品类型	By Route of Administration	By Disease Type	By Application	By Region
矿物盐的佐剂 Tensoactive Adjuvants 佐剂乳液 Liposome Adjuvants 碳水化合物佐剂 Bacteria-derived Adjuvants Virus-like Particles (VLP) Other Types	Oral 皮下来的 Intranasal Intramuscular Intradermal Others	Infectious Diseases Rare Diseases Cancer 自身免疫障碍 Others	研究应用程序 商业应用	North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Belgium, Austria) Asia Pacific (Japan, China, India, Malaysia, South Korea. Australia) Latin America (Brazil, Mexico, Argentina) MEA (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report:request for sample pages

Product Type Outlook

基于产品类型，全球市场分为基于矿物盐，硫酸盐，佐剂，脂质体，碳水化合物，衍生的，病毒等颗粒（VLP）和其他类型的佐剂。2019年，佐剂乳液分部占最大份额，也预计将在研究时间范围内注册最高增长率。

This segmental growth is attributed to various factors such as the rising prevalence of allergic reactions, higher efficiency of emulsion based adjuvants, and the strong focus of pharmaceutical companies. Moreover, adjuvant emulsions have higher clinical effectiveness owing to their small droplet size which enables immune cells to react quickly by activating innate immunity of the individual.

行政途径

On the basis of the route of administration, the global market is categorized into subcutaneous, intradermal, intranasal, oral, intramuscular, and others. In 2019, the intramuscular segment accounted for the largest share in the global market. This high share is due to the fact that delivery of most of the current vaccine in use through this mode. Most of the government sponsored immunization programs also prefer this route of administration.

Intradermal segment is expected to register the highest growth rate over the study timeframe. This high growth is due to the fact the skin layer is composed of immunologically supported antigen presenting cells (APCs) which increases the effectiveness of medicine in comparison with skeletal muscles having relatively sparse APCs. APCs are first instigators in activating the antibodies against antigens.

Disease Type Outlook

On the basis of disease type, the global market is categorized into infectious diseases, rare diseases, cancer, autoimmune disorders, and others. In 2019, the infectious diseases segment accounted for the largest share. The rising cases of infectious diseases across the globe and strong government intent towards R&D of autoimmune and cancer diseases driving the segment growth in the future years.

Government sponsored immunization programs are able to prevent deaths associated with infectious diseases such as pneumonia, polio, and measles but still each year, according to the estimates of World Health Organization (WHO) more than 1.5 million kids aged 5 lose their life to the vaccine preventable diseases.

应用前景

On the basis of application, the global market is categorized into research application and commercial application. In 2019, the research application segment accounted for the largest share and it is also anticipated to register the highest growth rate over the study timeframe. Growth in this segment is driven by the increasing incidence of zoonotic diseases and the ongoing research projects on adjuvants to further increase effectiveness of medicines.

For instance, in June 20, 2020, the researchers working at the Emory Vaccine Center in collaboration with Yerkes National Primate Research Center developed new adjuvant 3M-052. According to their claim published in the journal, Science Immunology, this adjuvant could increase immunity against HIV. This development might also have implications on successfully developing vaccines for influenza and the ongoing pandemic of COVID-19.

Regional Outlook

地理位置上，全球疫苗辅助市场被分叉进入北美，欧洲，亚太地区，拉丁美洲和中东和非洲（MEA）。北美地区是欧洲和亚太地区的最大收入贡献者。2019年，北美地区占全球市场的百分比。涉及佐剂研发，强大的政府资金和Covid-19案件的生物制药公司的存在是促进该地区市场增长的重要因素。

In May 2020, the U.S. government launched Operation Warp Speed (OWS). OWS is the federal government funded public private partnership to facilitate COVID-19 vaccine development, manufacturing and its distribution. OWS has the aim to support the production of more than 300 million COVID-19 doses by 2021, in collaboration with Johnson & Johnson, Moderna, AstraZeneca, Pfizer, and Merck. Moreover, in December 2019, Sanofi Pasteur, the vaccine business unit of the Sanofi signed an agreement with the U.S department of Health and Human Services (HHS) to invigorate the company’s domestic production capabilities for influenza vaccine.

In 2019, Europe accounted for the second largest share in the global market. The major revenue contributors in the region were UK, Germany, France, Italy, and Spain. The growing cases of COVID-19 in the region have made individual regimes to develop cure at a faster pace to reduce the number of casualties. The UK government had set up coronavirus vaccine taskforce for its development and large scale production, as it reported more than 14,576 deaths as of 17 April 2020.

With several European governments in line to develop COVID-19 vaccine, there are chances of “vaccine nationalism”. This is the case when an individual country prefers its own citizens over others to monopolize vaccine development. This is done through pre-purchase agreements between the vaccine developer and the individual government. In line with this, the German government in June 2020, had bought 23 percent stake in CureVac, the U.S. based bio-pharmaceutical company leading in the race to develop COVID-19 vaccine through an investment of USD340 million.

Asia Pacific is projected to be fastest growing regional market over the study timeframe. The factors responsible for the market in this region are sudden spike in the COVID-19 cases in India, China, South Korea, and Australia. India and China are the countries with the highest population density. Asian governments providing funding and other initiatives to tackle with the situation.

印度政府（GOI）已经分配了来自PM-Cares基金的100亿卢比用于开发Covid-19疫苗。目前，在此基金会有大约25个疫苗开发工作，与行业 - 学术协作有关。此外，中国在2020年4月，宣布额外资金为30百万美元，为处理Covid-19大流行。

Competitive Insight

全球市场充斥着小型和大型球员。在市场上运营的一些关键参与者是Glaxosmithkline Plc，Moderna Inc.，Sanofi Pasteur，Adjuvatis，Avanti Polar Lipids，Inc。，Spi Pharma，MPV Technologies，Novavavax，Inc。，Statens血清Institut，CSL Limited，Viscogel AB，VAXLIANT LLC，APHIOS CORPORATION，VAXINE PTY LTD，CUREVAC AG，SERGENT ACDUVANTANT，AGENUS，INC.，OZ BIOCIENCE，ADJUVANTS UNLIMITE INC.，以及佐剂EUCLID加拿大公司